

#DYK
Did you know?

Oncolytic viruses are engineered to selectively destroy cancer cells while sparing normal cells



Dual Mechanism of Action:
Direct tumor cell destruction and immune system activation



Advanced Delivery Systems:
Nanoparticle carriers improve targeting and stability



Genetic Engineering: Tailoring oncolytic virus therapy with tumor-specific promoters and immune enhancers




Applications:
Effective against solid tumors, melanoma, pancreatic, and glioblastoma cancers




Broadening applications to autoimmune diseases, neurological disorders, and infectious diseases

US dominates funding with **\$405.2M**, driving early-phase research and development


China and Canada follow as key contributors to **advancing global oncolytic virus therapy innovation**



TRIAL DISTRIBUTION:



TARGETED THERAPEUTIC AREAS:



2019 – 2024
Oncolytic virus therapy trials:
(CAGR: 14.2%)



Fastest CAGR Asia-Pacific:
(14.9%)



Trial Leaders:
US, Mainland China



Phase I (~50%)



Combination therapies are gaining the focus of innovators